SC 13G 1 tm216331d1_sc13g.htm SCHEDULE 13G

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. )*

I-MAB

(Name of Issuer)

Ordinary Shares, par value $0.0001**

American Depositary Shares

(Title of Class of Securities)

44975P103^**

(CUSIP Number)

December 31, 2020

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)

¨ Rule 13d-1(c)

x Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

** There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 44975P103 has been assigned to the ADSs of the Issuer, which are quoted on the Nasdaq Global Market under the symbol “IMAB.” Each 10 ADSs represents 23 Ordinary Shares.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 44975P103

SCHEDULE 13G

Page 2 of 17 Pages

1	NAMES OF REPORTING PERSONS IBC Investment Seven Limited
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Hong Kong
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER 0
		6	SHARED VOTING POWER 3,931,802
		7	SOLE DISPOSITIVE POWER 0
		8	SHARED DISPOSITIVE POWER 3,931,802
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,931,802
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 2.4%¹
12	TYPE OF REPORTING PERSON CO

¹ Based upon 165,477,620 ordinary shares of the Issuer reported to be outstanding in the Issuer’s Rule 424(b)(5) prospectus, filed with the SEC on February 9, 2021.

CUSIP No. 44975P103

SCHEDULE 13G

Page 3 of 17 Pages

1	NAMES OF REPORTING PERSONS CBC SPVII LIMITED
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Hong Kong
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER 0
		6	SHARED VOTING POWER 5,574,560
		7	SOLE DISPOSITIVE POWER 0
		8	SHARED DISPOSITIVE POWER 5,574,560
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,574,560
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.4%²
12	TYPE OF REPORTING PERSON CO

²Based upon 165,477,620 ordinary shares of the Issuer reported to be outstanding in the Issuer’s Rule 424(b)(5) prospectus, filed with the SEC on February 9, 2021.

CUSIP No. 44975P103

SCHEDULE 13G

Page 4 of 17 Pages

1	NAMES OF REPORTING PERSONS CBC Investment I-Mab Limited
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION British Virgin Islands
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER 0
		6	SHARED VOTING POWER 12,229,916
		7	SOLE DISPOSITIVE POWER 0
		8	SHARED DISPOSITIVE POWER 12,229,916
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 12,229,916
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.4%³
12	TYPE OF REPORTING PERSON CO

³ Based upon 165,477,620 ordinary shares of the Issuer reported to be outstanding in the Issuer’s Rule 424(b)(5) prospectus, filed with the SEC on February 9, 2021.

CUSIP No. 44975P103

SCHEDULE 13G

Page 5 of 17 Pages

1	NAMES OF REPORTING PERSONS C-Bridge II Investment Ten Limited
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) ý
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION British Virgin Islands
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER 0
		6	SHARED VOTING POWER 2,369,546
		7	SOLE DISPOSITIVE POWER 0
		8	SHARED DISPOSITIVE POWER 2,369,546
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,369,546
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 1.4%⁴
12	TYPE OF REPORTING PERSON CO

⁴Based upon 165,477,620 ordinary shares of the Issuer reported to be outstanding in the Issuer’s Rule 424(b)(5) prospectus, filed with the SEC on February 9, 2021.

CUSIP No. 44975P103

SCHEDULE 13G

Page 6 of 17 Pages

1	NAMES OF REPORTING PERSONS Everest Medicines Limited
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER 0
		6	SHARED VOTING POWER 6,078,571
		7	SOLE DISPOSITIVE POWER 0
		8	SHARED DISPOSITIVE POWER 6,078,571
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,078,571
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.7%⁵
12	TYPE OF REPORTING PERSON CO

⁵ Based upon 165,477,620 ordinary shares of the Issuer reported to be outstanding in the Issuer’s Rule 424(b)(5) prospectus, filed with the SEC on February 9, 2021.

CUSIP No. 44975P103

SCHEDULE 13G

Page 7 of 17 Pages

1	NAMES OF REPORTING PERSONS C-Bridge II Investment Thirteen Limited
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION British Virgin Islands
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER 0
		6	SHARED VOTING POWER 859,181
		7	SOLE DISPOSITIVE POWER 0
		8	SHARED DISPOSITIVE POWER 859,181
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 859,181⁶
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.5%⁷
12	TYPE OF REPORTING PERSON CO

⁶ Represented by 373,557 American depositary shares of the Issuer

⁷ Based upon 165,477,620 ordinary shares of the Issuer reported to be outstanding in the Issuer’s Rule 424(b)(5) prospectus, filed with the SEC on February 9, 2021.

CUSIP No. 44975P103

SCHEDULE 13G

Page 8 of 17 Pages

1	NAMES OF REPORTING PERSONS C-Bridge Healthcare Fund II, L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) ý
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER 0
		6	SHARED VOTING POWER 15,458,643
		7	SOLE DISPOSITIVE POWER 0
		8	SHARED DISPOSITIVE POWER 15,458,643
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 15,458,643⁸
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.3%⁹
12	TYPE OF REPORTING PERSON PN

⁸ Including 859,181 ordinary shares represented by 373,557 American depositary shares of the Issuer

⁹ Based upon 165,477,620 ordinary shares of the Issuer reported to be outstanding in the Issuer’s Rule 424(b)(5) prospectus, filed with the SEC on February 9, 2021.

CUSIP No. 44975P103

SCHEDULE 13G

Page 9 of 17 Pages

1	NAMES OF REPORTING PERSONS C-Bridge Healthcare Fund GP II, L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) ý
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER 0
		6	SHARED VOTING POWER 15,458,643
		7	SOLE DISPOSITIVE POWER 0
		8	SHARED DISPOSITIVE POWER 15,458,643
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 15,458,643¹⁰
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.3%¹¹
12	TYPE OF REPORTING PERSON PN

¹⁰Including 859,181 ordinary shares represented by 373,557 American depositary shares of the Issuer

¹¹Based upon 165,477,620 ordinary shares of the Issuer reported to be outstanding in the Issuer’s Rule 424(b)(5) prospectus, filed with the SEC on February 9, 2021.

CUSIP No. 44975P103

SCHEDULE 13G

Page 10 of 17 Pages

1	NAMES OF REPORTING PERSONS C-Bridge Capital GP, Ltd.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) ý
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER 0
		6	SHARED VOTING POWER 24,965,005
		7	SOLE DISPOSITIVE POWER 0
		8	SHARED DISPOSITIVE POWER 24,965,005
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 24,965,005¹²
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 15.1%¹³
12	TYPE OF REPORTING PERSON CO

¹² Including 859,181 ordinary shares represented by 373,557 American depositary shares of the Issuer

¹³ Based upon 165,477,620 ordinary shares of the Issuer reported to be outstanding in the Issuer’s Rule 424(b)(5) prospectus, filed with the SEC on February 9, 2021.

CUSIP No. 44975P103

SCHEDULE 13G

Page 11 of 17 Pages

1	NAMES OF REPORTING PERSONS I-Bridge Healthcare Fund, L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) ý
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands

NUMBER OF

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH

SOLE VOTING POWER

SHARED VOTING POWER

9,506,362

SOLE DISPOSITIVE POWER

SHARED DISPOSITIVE POWER

9,506,362

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9,506,362
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.7%¹⁴
12	TYPE OF REPORTING PERSON PN

¹⁴ Based upon 165,477,620 ordinary shares of the Issuer reported to be outstanding in the Issuer’s Rule 424(b)(5) prospectus, filed with the SEC on February 9, 2021.

CUSIP No. 44975P103

SCHEDULE 13G

Page 12 of 17 Pages

1	NAMES OF REPORTING PERSONS I-Bridge Healthcare GP, L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) ý
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands

NUMBER OF

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH

SOLE VOTING POWER

SHARED VOTING POWER

9,506,362

SOLE DISPOSITIVE POWER

SHARED DISPOSITIVE POWER

9,506,362

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9,506,362
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.7% ¹⁵
12	TYPE OF REPORTING PERSON PN

¹⁵ Based upon 165,477,620 ordinary shares of the Issuer reported to be outstanding in the Issuer’s Rule 424(b)(5) prospectus, filed with the SEC on February 9, 2021.

CUSIP No. 44975P103

SCHEDULE 13G

Page 13 of 17 Pages

1	NAMES OF REPORTING PERSONS I-Bridge Capital GP, Ltd.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) ý
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands

NUMBER OF

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH

SOLE VOTING POWER

SHARED VOTING POWER

9,506,362

SOLE DISPOSITIVE POWER

SHARED DISPOSITIVE POWER

9,506,362

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9,506,362
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.7%¹⁶
12	TYPE OF REPORTING PERSON CO

¹⁶ Based upon 165,477,620 ordinary shares of the Issuer reported to be outstanding in the Issuer’s Rule 424(b)(5) prospectus, filed with the SEC on February 9, 2021.

CUSIP No. 44975P103

SCHEDULE 13G

Page 14 of 17 Pages

1	NAMES OF REPORTING PERSONS Wei Fu
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) ý
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Singapore

NUMBER OF

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH

SOLE VOTING POWER

SHARED VOTING POWER

31,043,576

SOLE DISPOSITIVE POWER

SHARED DISPOSITIVE POWER

31,043,576

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 31,043,576¹⁷
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 18.8%¹⁸
12	TYPE OF REPORTING PERSON IN

¹⁷ Including 859,181 ordinary shares represented by 373,557 American depositary shares of the Issuer

¹⁸ Based upon 165,477,620 ordinary shares of the Issuer reported to be outstanding in the Issuer’s Rule 424(b)(5) prospectus, filed with the SEC on February 9, 2021.

CUSIP No. 44975P103

SCHEDULE 13G

Page 15 of 17 Pages

Item 1(a)

Name of Issuer:

I-MAB (the “Issuer”)

Item 1(b)

Address of Issuer’s Principal Executive Offices:

Suite 802, West Tower, OmniVision

88 Shangke Road, Pudong District

Shanghai, 201210

People’s Republic of China

Item 2(a)

Name of Persons Filing:

This Schedule 13G is filed by and on behalf of:

IBC Investment Seven Limited

CBC SPVII LIMITED

CBC Investment I-Mab Limited

C-Bridge II Investment Ten Limited

Everest Medicines Limited

C-Bridge II Investment Thirteen Limited

C-Bridge Healthcare Fund II, L.P.

C-Bridge Healthcare Fund GP II, L.P.

C-Bridge Capital GP, Ltd.

10.

I-Bridge Healthcare Fund, L.P.

11.

I-Bridge Healthcare GP, L.P.

12.

I-Bridge Capital GP, Ltd.

13.

Wei Fu

This statement on Schedule 13G relates to securities directly held by IBC Investment Seven Limited, CBC SPVII LIMITED, CBC Investment I-Mab Limited, C-Bridge II Investment Ten Limited, Everest Medicines Limited, and C-Bridge II Investment Thirteen Limited.

CBC Investment I-Mab Limited, C-Bridge II Investment Ten Limited and C-Bridge II Investment Thirteen Limited are controlled by C-Bridge Healthcare Fund II, L.P., whose general partner is C-Bridge Healthcare Fund GP II, L.P., and its general partner is C-Bridge Capital GP, Ltd.

CBC SPVII Limited and IBC Investment Seven Limited are controlled by I-Bridge Healthcare Fund, L.P., whose general partner is I-Bridge Healthcare GP, L.P., and its general partner is I-Bridge Capital GP, Ltd., which is indirectly controlled by C-Bridge Capital GP, Ltd.

Mr. Wei Fu is the sole director of C-Bridge Capital GP, Ltd.

CUSIP No. 44975P103

SCHEDULE 13G

Page 16 of 17 Pages

Everest Medicines Limited is a public company listed on the Hong Kong Stock Exchange and controlled by funds which are under common control of the C-Bridge group, which, in turn, is controlled by Mr. Wei Fu.

C-Bridge Healthcare Fund II, L.P., C-Bridge Healthcare Fund GP II, L.P., C-Bridge Capital GP, Ltd., I-Bridge Healthcare Fund, L.P., I-Bridge Healthcare GP, L.P., I-Bridge Capital GP, Ltd., and Mr. Wei Fu may be deemed to beneficially own the securities of the Issuer owned by the entities which they control.

Item 2(b)

Address of Principal Business Office or, If None, Residence

The business address of each reporting person is Suite 3306-3307, Two Exchange Square, 8 Connaught Place, Central, Hong Kong.

Item 2(c)

Citizenship

IBC Investment Seven Limited: Hong Kong

CBC SPVII LIMITED: Hong Kong

CBC Investment I-Mab Limited: British Virgin Islands

C-Bridge II Investment Ten Limited: British Virgin Islands

Everest Medicines Limited: Cayman Islands

C-Bridge II Investment Thirteen Limited: British Virgin Islands

C-Bridge Healthcare Fund II, L.P.: Cayman Islands

C-Bridge Healthcare Fund GP II, L.P.: Cayman Islands

C-Bridge Capital GP, Ltd.: Cayman Islands

10.

I-Bridge Healthcare Fund, L.P.: Cayman Islands

11.

I-Bridge Healthcare GP, L.P.: Cayman Islands

12.

I-Bridge Capital GP, Ltd.: Cayman Islands

13.

Wei Fu: Singapore

Item 2(d)

Title of Class of Securities:

Ordinary Shares, par value $0.0001

Item 2(e)

CUSIP Number:

44975P103

Item 3.

Statement Filed Pursuant to Rule 13d-1(b) or 13d-2(b) or (c):

Not applicable.

Item 4.

Ownership

The information for each reporting person contained in rows 5-11 of the cover pages and Item 2(a) is incorporated herein by reference.

CUSIP No. 44975P103

SCHEDULE 13G

Page 17 of 17 Pages

Item 5.

Ownership of Five Percent or Less of a Class

Not applicable.

Item 6.

Ownership of More Than Five Percent on Behalf of Another Person

Not applicable.

Item 7.

Identification and Classification of Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

Not applicable.

Item 8.

Identification and Classification of Members of the Group

Not applicable.

Item 9.

Notice of Dissolution of Group

Not applicable.

Item 10.

Certifications

Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 12, 2021

	IBC Investment Seven Limited

	By:	/s/ Wei FU
	Name:	Wei FU
	Title:	Director

	CBC SPVII LIMITED

	By:	/s/ Wei FU
	Name:	Wei FU
	Title:	Director

	CBC Investment I-Mab Limited

	By:	/s/ Wei FU
	Name:	Wei FU
	Title:	Director

	C-Bridge II Investment Ten Limited

	By:	/s/ Wei FU
	Name:	Wei FU
	Title:	Director

	Everest Medicines Limited

	By:	/s/ Xiaofan ZHANG
	Name:	Xiaofan ZHANG
	Title:	Director

	C-Bridge II Investment Thirteen Limited


	By:	/s/ Wei FU
	Name:	Wei FU
	Title:	Director

	C-Bridge Healthcare Fund II, L.P.

	By:	/s/ Wei FU
	Name:	Wei FU
	Title:	Authorized Representative

	C-Bridge Healthcare Fund GP II, L.P.

	By:	/s/ Wei FU
	Name:	Wei FU
	Title:	Authorized Representative

	C-Bridge Capital GP, Ltd.

	By:	/s/ Wei FU
	Name:	Wei FU
	Title:	Director

	I-Bridge Healthcare Fund, L.P.

	By:	/s/ Wei FU
	Name:	Wei FU
	Title:	Authorized Representative

	I-Bridge Healthcare GP, L.P.

	By:	/s/ Wei FU
	Name:	Wei FU
	Title:	Authorized Representative

	I-Bridge Capital GP, Ltd.

	By:	/s/ Wei FU
	Name:	Wei FU
	Title:	Director

	Wei Fu

	By:	/s/ Wei FU

LIST OF EXHIBITS

Exhibit No. Description

Joint Filing Agreement dated as of February 12, 2021 by and among the reporting persons

Exhibit 1

Joint Filing Agreement

In accordance with Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Ordinary Shares, par value $0.0001, of I-MAB and further agree that this Joint Filing Agreement shall be included as an Exhibit to such joint filing. In evidence thereof, the undersigned, being duly authorized, hereby execute this Joint Filing Agreement as of February 12, 2021. This Agreement may be executed in any number of counterparts, all of which, taken together, shall constitute one and the same instrument.

	IBC Investment Seven Limited


	By:	/s/ Wei FU
	Name:	Wei FU
	Title:	Director

	CBC SPVII LIMITED


	By:	/s/ Wei FU
	Name:	Wei FU
	Title:	Director

	CBC Investment I-Mab Limited


	By:	/s/ Wei FU
	Name:	Wei FU
	Title:	Director

	C-Bridge II Investment Ten Limited


	By:	/s/ Wei FU
	Name:	Wei FU
	Title:	Director

	Everest Medicines Limited


	By:	/s/ Xiaofan ZHANG
	Name:	Xiaofan ZHANG
	Title:	Director

	C-Bridge II Investment Thirteen Limited


	By:	/s/ Wei FU
	Name:	Wei FU
	Title:	Director

	C-Bridge Healthcare Fund II, L.P.


	By:	/s/ Wei FU
	Name:	Wei FU
	Title:	Authorized Representative

	C-Bridge Healthcare Fund GP II, L.P.


	By:	/s/ Wei FU
	Name:	Wei FU
	Title:	Authorized Representative

	C-Bridge Capital GP, Ltd.


	By:	/s/ Wei FU
	Name:	Wei FU
	Title:	Director

	I-Bridge Healthcare Fund, L.P.


	By:	/s/ Wei FU
	Name:	Wei FU
	Title:	Authorized Representative

	I-Bridge Healthcare GP, L.P.


	By:	/s/ Wei FU
	Name:	Wei FU
	Title:	Authorized Representative

	I-Bridge Capital GP, Ltd.


	By:	/s/ Wei FU
	Name:	Wei FU
	Title:	Director

	Wei Fu


	By:	/s/ Wei FU

SEC Form SC 13G filed